Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05102773 · ClinicalTrials.gov registry record
The Effect of the Microbiome on Immune Checkpoint Inhibitor Response in Melanoma Patients
A clinical trial of Clinical Stage IV Cutaneous Melanoma AJCC v8 and Pathologic Stage IV Cutaneous Melanoma AJCC v8, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- 88
- Enrollment target
- 1
- Study location
NCT05102773 is a study of Clinical Stage IV Cutaneous Melanoma AJCC v8 and Pathologic Stage IV Cutaneous Melanoma AJCC v8 that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 88 participants, below the 149-participant average among 32 other Clinical Stage IV Cutaneous Melanoma AJCC v8 trials with a reported enrollment target (41% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05102773, a study of Clinical Stage IV Cutaneous Melanoma AJCC v8 and Pathologic Stage IV Cutaneous Melanoma AJCC v8, has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- 88 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot trial studies the effect of the microbiome on immune checkpoint inhibitors response in patients with melanoma by collecting stool and blood samples. Gut microbiome plays a critical role in response to immune checkpoint inhibitors. Studying the change in an individual's microbiome due to corticosteroid use may help researchers to determine whether an individual's microbiome can predict their response and toxicity to immune checkpoint inhibitors.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- OTHER Laboratory Biomarker Analysis
- OTHER Questionnaire Administration
Study Locations (1)
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2020-02-10 |
| Est. Completion | 2022-05-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05102773
The ClinicalTrials.gov registry entry for NCT05102773 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 149-participant average among 32 other Clinical Stage IV Cutaneous Melanoma AJCC v8 trials with a reported enrollment target (41% lower). The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Clinical Stage IV Cutaneous Melanoma AJCC v8 appearing as the primary indexed condition, and to 4 interventions - of which Biospecimen Collection is the first listed.
NCT05102773 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT05102773 about?
NCT05102773 is a clinical study titled "The Effect of the Microbiome on Immune Checkpoint Inhibitor Response in Melanoma Patients". This pilot trial studies the effect of the microbiome on immune checkpoint inhibitors response in patients with melanoma by collecting stool and blood samples. Gut microbiome plays a critical role in response to immune checkpoint inhibitors. Studying the change in an individual's microbiome due to c...
What is the current status of trial NCT05102773?
This trial is currently completed. The enrollment target is 88 participants. The study started on 2020-02-10. Estimated completion is 2022-05-05.
What conditions does trial NCT05102773 study?
This clinical trial studies the following conditions: Clinical Stage IV Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8.
What interventions are being tested in trial NCT05102773?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Laboratory Biomarker Analysis (OTHER), Questionnaire Administration (OTHER).
Who is sponsoring clinical trial NCT05102773?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05102773 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clinical Stage IV Cutaneous Melanoma AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
RECRUITING · Phase 1
-
Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial
RECRUITING · Phase 2
-
Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
RECRUITING · Phase 1
-
The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors
RECRUITING · Phase 1
-
Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types
RECRUITING
-
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
RECRUITING · Phase 2
Explore more on PlainTrial
Clinical Stage IV Cutaneous Melanoma AJCC v8
All registered trials for this condition
Pathologic Stage IV Cutaneous Melanoma AJCC v8
All registered trials for this condition
Ohio
All trials with a study site in Ohio
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.